Endotracheal Application of Ultraviolet A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2: A First-in-Human Study
2021; Adis, Springer Healthcare; Volume: 38; Issue: 8 Linguagem: Inglês
10.1007/s12325-021-01830-7
ISSN1865-8652
AutoresAli Rezaie, Gil Y. Melmed, Gabriela Leite, Ruchi Mathur, Will Takakura, Isabel Pedraza, Michael I. Lewis, Rekha Murthy, George Chaux, Mark Pimentel,
Tópico(s)Infection Control and Ventilation
ResumoOur previous preclinical experiments show that under specific and monitored conditions, ultraviolet A (UVA) exposure reduces certain bacteria, fungi, and viruses including coronavirus-229E without harming mammalian columnar epithelial cells. The goal of this study was to evaluate the safety and effects of narrow-band UVA therapy administered by a novel device via endotracheal tube in critically ill subjects with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Referência(s)